Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations

Oncogene

Volumn 27, Issue 22, 2008, Pages 3201-3210

  Cai, C Q ^a   Peng, Y ^a   Buckley, M T ^a   Wei, J ^a   Chen, F ^a   Liebes, L ^a   Gerald, W L ^b   Pincus, M R ^c,d   Osman, I ^a   Lee, P ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

EGFR; Mutation; Prostate cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PROTEIN KINASE B; STAT3 PROTEIN;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; MOLECULAR CLONING; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SOMATIC MUTATION; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CLONING, MOLECULAR; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; NIH 3T3 CELLS; PROSTATIC NEOPLASMS; PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR STEM CELL ASSAY;

EID: 43749096126     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210983     Document Type: Article

References (34)

1. Arteaga CL. (2006). EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell 9: 421-423.
2. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF. (2004). Signal transducer and activator of transcription 3(STAT3 ) activation in prostate cancer: direct STAT3inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 3: 11-20.
3. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW et al. (2005). Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23: 8081-8092.
4. Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H et al. (2006). Suppressor of cytokine signaling-3antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol 169: 2199-2208.
5. Choi SH, Mendrola JM, Lemmon MA. (2007). EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene 26: 1567-1576.
6. Chu YW, Runyan RB, Oshima RG, Hendrix MJ. (1993). Expression of complete keratin filaments in mouse L cells augments cell migration and invasion. Proc Natl Acad Sci USA 90: 4261-4265.
7. Citri A, Yarden Y. (2006). EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516.
8. Danielsen AJ, Maihle NJ. (2002). Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity. Exp Cell Res 275: 9-16.
9. DeMiguel F, Lee SO, Lou W, Xiao X, Pflug BR, Nelson JB et al. (2002). Stat3enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate 52: 123-129.
10. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR et al. (1987). Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51: 1063-1070.
11. Douglas D, Zhong H, Ro J, Oddoux C, Berger A, Pincus M et al. (2006). Racial difference in somatic mutations of epidermal growth factor receptor in prostate cancer. Front Biosci 11: 2518-2525.
12. Giri D, Ozen M, Ittmann M. (2001). Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159: 2159-2165.
13. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M et al. (2005). Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2: e313.
14. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70.
15. Huang HF, Murphy TF, Shu P, Barton AB, Barton BE. (2005). Stable expression of constitutively-activated STAT3in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells. Mol Cancer 4: 2.
16. Hubbard SR. (2005). EGF receptor inhibition: attacks on multiple fronts. Cancer Cell 7: 287-288.
17. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. (2003). Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 284: 31-53.
18. Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, Debiasi RM et al. (2006). Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3: e485.
19. Lee JW, Soung YH, Kim SY, Nam HK, Park WS, Nam SW et al. (2005). Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11: 2879-2882.
20. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
21. Nagahara H, Mimori K, Ohta M, Utsunomiya T, Inoue H, Barnard GF et al. (2005). Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 11: 1368-1371.
22. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
23. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. (2004). EGFR receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311.
24. Ratan HL, Gescher A, Steward WP, Mellon JK. (2003). ErbB receptors: possible therapeutic targets in prostate cancer? BJU Int 92: 890-895.
25. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E et al. (1994). A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370: 61-65.
26. Schreiber AB, Libermann TA, Lax I, Yarden Y, Schlessinger J. (1983). Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies. J Biol Chem 258: 846-853.
27. Shao H, Cheng HY, Cook RG, Tweardy DJ. (2003). Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 63: 3923-3930.
28. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C. (1998). Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 77: 855-861.
29. Sordella R, Bell DW, Haber DA, Settleman J. (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167.
30. Spiotto MT, Chung TD. (2000). STAT3mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 42: 88-98.
31. Torring N, Dagnaes-Hansen F, Sorensen BS, Nexo E, Hynes NE. (2003). ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. Prostate 56: 142-149.
32. Ushiro H, Cohen S. (1980). Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J Biol Chem 255: 8363-8365.
33. Yarden Y, Sliwkowski MX. (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
34. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149.